Invention Grant
- Patent Title: Heteroaryl substituted nicotinamide compounds
- Patent Title (中): 杂芳基取代的烟酰胺化合物
-
Application No.: US14588470Application Date: 2015-01-02
-
Publication No.: US09169252B2Publication Date: 2015-10-27
- Inventor: Joseph B. Santella , Sreekantha Ratna Kumar , John V. Duncia , Daniel S. Gardner , Venkatram Reddy Paidi , Satheesh Kesavan Nair , John Hynes , Hong Wu , Natesan Murugesan , Kandhasamy Sarkunam , Piramanayagam Arunachalam
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Gary D. Greenblatt
- Main IPC: C07D213/02
- IPC: C07D213/02 ; C07D519/00 ; C07D401/14 ; C07D471/04 ; C07D401/04 ; C07D487/04 ; C07F9/6561

Abstract:
Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Ra and Rb; and R1 and R2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.
Public/Granted literature
- US20150191464A1 HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS Public/Granted day:2015-07-09
Information query